cure for Alzheimer’s disease "promising" He does not reach his goal and shatters the hopes of scientists for a cure for a deadly disease.

The pharmaceutical giant has announced that two Phase 3 trials of a potential Alzheimer’s drug have failed to meet their goal of slowing clinical decline in participants in the early stages of the disease.

And I paid Swiss pharmaceutical company Roche Two identical phase 3 gantenerumab clinical trials with about 1000 volunteers each.

#MASS MEDIAConclusions from two of our phase III clinical trials in #Alzheimer’s disease there is now available. Although the trials have not reached their end points, we remain seeks to make a significant contribution to the lives of all those affected by this disease. Read more:

– Roche (@Roche) November 14, 2022

Experts had hoped for positive results from the clinical trials of Roche Graduate 1 and Roche Graduate 2, but Alzheimer’s hopes for a cure have been dealt another blow when the experimental drug failed to slow the progression of the disease.

Dr Susan Koolhaas, director of research at Alzheimer’s Research UK, said: “People with Alzheimer’s are desperate for more effective treatment options, so it’s extremely disappointing that a potential drug hasn’t delivered the benefits we hoped to see.” The manufacturer of the drug, the company “Roche”. , will soon present the results of this trial. This will allow the research community to learn from them to help develop a cure for Alzheimer’s in the future.”

She added: “Gantenerumab is one of several drugs designed to remove the hallmark of Alzheimer’s disease, the amyloid protein, from people’s brains in the earliest stages of the disease.”

Today we heard disappointment news from the Alzheimer’s drug, gantenerumab, phase 3 clinical trials.

Despite this, there is still a huge amount of hope in dementia research and this critical that the UK government delivers on his promise double dementia research financing.

— AlzheimersResearchUK 🍊 (@AlzResearchUK) November 14, 2022

She continued, “Earlier this year, the final phase of a trial of another anti-amyloid drug called lekanemab cleared the brain of amyloid and slowed the decline in participants’ memory and thinking skills. from the lekanemab and gantenerumab trials will demonstrate understanding. The mission is to find out why one anti-amyloid drug works better than another, and this will help improve this approach to treating people with Alzheimer’s disease.”

Notably, gantenerumab is an antibody-based drug that showed great promise when it entered phase III clinical trials. However, Roche reports that the injectable drug failed to clearly show that it slows the progression of this common form of dementia in two trials of the drug.

Previous data have shown that gantenerumab reduces amyloid deposits in the brain.

Abnormal levels of normal amyloid protein accumulate in the brains of people with Alzheimer’s disease, forming plaques that build up between nerve cells and impair cell function.

Roche’s new clinical trials included more than 2,000 patients treated for more than two years in over 30 countries.

Muriel de Vos of Roche said: “We are disappointed with the initial results of pivotal Phase 3 I and II studies showing that the primary endpoint of slowing down clinical deterioration has not been reached. However, we remain committed to changing people’s lives. with Alzheimer’s disease through our research Continuous development of experimental drugs for different targets, types and stages of Alzheimer’s disease.

New data shows #gantenerumab failed to reach its main endpoint. Although anti-amyloid therapy is the starting point, there is an emergency need develop new generation of drugs that target the whole body of underlying #Alzheimer’s causes. See the ADDF statement:

— Alzheimer’s Drug Discovery Foundation (@TheADDF) November 14, 2022

Dr. Koolhaas added: “Alzheimer’s disease is complex, and potential drugs that target other aspects of the disease are also in clinical trials. There are more than 140 potential Alzheimer’s drugs in clinical trials, most of which target proteins or processes other than amyloid.”

Source: Medical Express + The Independent.